present
case
woman
symptomat
cytomegaloviru
cmv
infect
daratumumab
monotherapi
treatment
relapsedrefractori
multipl
myeloma
mm
patient
diagnos
monoclon
gammopathi
unknown
signific
progress
smolder
mm
symptomat
mm
requir
system
treatment
august
diseas
relaps
refractori
immunomodulatori
agent
thalidomid
lenalidomid
pomalidomid
bortezomib
alkyl
melphalan
cyclophosphamid
well
antibodi
elotuzumab
time
daratumumab
monotherapi
mgkg
initi
seventh
line
treatment
infus
present
fever
histori
physic
examin
reveal
sign
infect
blood
urin
sputum
cultur
neg
microorgan
chest
xray
show
pulmonari
infiltr
treat
empir
broadspectrum
antibiot
amoxicillinclavulan
week
peripher
insert
central
venou
cathet
remov
pathogen
cultur
tip
persist
fever
addit
diagnost
test
perform
repeat
laboratori
examin
show
abnorm
evid
mycobacteri
diseas
respiratori
virus
influenza
viru
ab
metapneumoviru
respiratori
syncyti
viru
parainfluenza
viru
type
rhinoviru
coronaviru
comput
tomographi
scan
chest
abdomen
part
diagnost
workup
fever
unknown
origin
reveal
explan
symptom
meanwhil
clinic
condit
deterior
develop
night
sweat
anorexia
weight
loss
kg
fatigu
time
platelet
count
l
hemoglobin
level
mmoll
decreas
absenc
neutropenia
upon
develop
chill
week
first
report
fever
admit
hospit
repeat
cultur
blood
urin
sputum
remain
neg
microorgan
given
persist
fever
immunocompromis
statu
point
inconclus
workup
analyz
potenti
reactiv
viral
infect
epsteinbarr
viru
dna
present
blood
sampl
howev
high
level
cmvdna
detect
blood
quantit
polymeras
chain
reaction
assay
copiesml
indic
symptomat
cmv
infect
cmv
endorgan
diseas
pneumon
hepat
report
abdomin
discomfort
diarrhea
coincid
onset
report
case
symptomat
cytomegaloviru
cmv
reactiv
upon
initi
daratumumab
monotherapi
treatment
heavili
pretreat
patient
multipl
myeloma
mm
patient
mm
risk
cmv
reactiv
increas
follow
autolog
stem
cell
transplant
limit
data
avail
incid
cmv
reactiv
patient
mm
receiv
stem
cell
transplant
knowledg
first
report
symptomat
cmv
reactiv
daratumumab
monotherapi
treatment
although
routin
monitor
cmv
recommend
possibl
cmv
reactiv
consid
patient
mm
treat
daratumumab
infecti
symptom
otherwis
explain
fever
suggest
possibl
cmvcoliti
howev
refus
endoscop
evalu
diagnosi
could
confirm
importantli
serolog
antibodi
test
alreadi
show
posit
cmvspecif
igg
indic
cmv
reactiv
primari
infect
current
situat
treatment
intraven
ganciclovir
mgkg
twice
daili
initi
result
normal
temperatur
within
hour
hour
cmvdna
load
decreas
copiesml
discharg
continu
valganciclovir
oral
mg
twice
daili
month
diagnosi
cmvdna
load
repeatedli
detect
limit
copiesml
eventu
becam
neg
symptom
recur
time
platelet
count
hemoglobin
level
return
baselin
valu
diarrhea
resolv
symptomat
cmv
reactiv
occur
patient
alreadi
achiev
partial
respons
daratumumab
treatment
owe
extens
mm
treatment
histori
altern
treatment
option
limit
would
induc
addit
immunosuppress
combin
rapid
respons
ganciclovir
treatment
led
decis
continu
daratumumab
accord
recommend
schedul
regular
monitor
cmvdna
load
time
dexamethason
given
infusionrel
reaction
prophylaxi
taper
achiev
good
partial
respons
durat
month
cmv
dnaload
remain
neg
describ
patient
suffer
symptomat
cmv
infect
upon
initi
daratumumab
monotherapi
treatment
risk
recurr
cmv
infect
increas
immunocompromis
patient
patient
primari
immunodefici
hiv
infect
solid
organ
transplant
recipi
patient
hemodialysi
patient
hematolog
disord
risk
cmv
infect
markedli
increas
follow
allogen
stem
cell
transplant
autolog
stem
cell
transplant
asct
select
cell
well
follow
treatment
highdos
corticosteroid
alemtuzumab
cladribin
fludarabin
result
lower
level
dysfunct
natur
killer
nk
cell
tcell
tcell
patient
mm
increas
suscept
infect
result
myelomainduc
immun
dysfunct
includ
impair
tand
nkcell
activ
decreas
polyclon
immunoglobulin
product
well
cumul
immunosuppress
antimm
treatment
regimen
incid
cmv
dnaemia
defin
presenc
cmvdna
without
cmvrelat
symptom
cmv
diseas
patient
mm
best
studi
follow
asct
prospect
studi
incid
cmvdnaemia
without
cmvrelat
symptom
postasct
rang
given
low
rate
patient
cmvdnaemia
develop
symptomat
cmv
infect
prospect
monitor
cmv
titer
patient
recommend
cmvdna
quantif
perform
clinic
indic
rate
symptomat
cmv
infect
postasct
rang
bortezomibcontain
induct
regimen
associ
higher
incid
cmv
reactiv
postasct
daratumumab
monoclon
igg
kappa
antibodi
target
highli
ubiquit
express
mm
cell
daratumumab
induc
kill
tumor
cell
via
classic
fcdepend
immun
effector
mechan
furthermor
daratumumab
deplet
regulatori
tcell
regulatori
bcell
myeloidderiv
suppressor
cell
lead
increas
tcell
number
clonal
tcell
expans
may
result
improv
hosteantitumor
immun
respons
daratumumab
high
singleag
efficaci
heavili
pretreat
patient
mm
relaps
andor
refractori
immunomodulatori
agent
proteasom
inhibitor
combin
well
sever
standard
care
daratumumab
monotherapi
infectionrel
seriou
advers
event
occur
patient
treat
trial
similar
trial
patient
discontinu
treatment
owe
infect
daratumumab
combin
bortezomibdexamethason
incid
grade
infect
slightli
higher
compar
daratumumab
monotherapi
similar
bortezomibdexamethason
control
group
compar
wherea
patient
treat
daratumumab
lenalidomidedexamethason
risk
higher
compar
lenalidomidedexamethason
alon
vs
studi
incid
pneumonia
differ
patient
treat
daratumumabbas
combin
treat
lenalidomidedexamethason
bortezomibdexamethason
alon
cmv
infect
report
daratumumab
monotherapi
treatment
cmv
reactiv
patient
thought
result
cumul
immunosuppress
effect
prior
mm
treatment
combin
daratumumabmedi
effect
inde
addit
investig
perform
directli
diagnosi
cmv
reactiv
show
low
tcell
ml
refer
valu
ml
bcell
count
ml
refer
valu
ml
probabl
result
treatment
pomalidomid
plu
lowdos
cyclophosphamid
dexamethason
prior
daratumumab
therapi
tabl
addit
daratumumab
shown
rapidli
decreas
nk
cell
count
occur
patient
alreadi
evid
cmv
reactiv
mm
patient
daratumumab
treatment
first
infus
inde
patient
low
number
circul
nk
cell
peripher
blood
ml
refer
valu
ml
tabl
character
potenti
cmv
reactiv
daratumumab
treatment
perform
quantit
cmvdna
polymeras
chain
reaction
crosssect
manner
patient
relapsedrefractori
mm
median
prior
line
treatment
rang
treat
daratumumab
singl
agent
cmvdnaemia
patient
altogeth
routin
screen
cmv
seem
benefici
patient
treat
daratumumab
howev
possibl
cmv
reactiv
taken
consider
case
unexplain
fever
bone
marrow
suppress
occur
patient
sign
suggest
cmv
endorgan
diseas
conclus
best
knowledg
report
first
time
patient
develop
fever
diarrhea
anemia
thrombocytopenia
owe
cmv
reactiv
daratumumab
monotherapi
treatment
associ
low
tcell
nk
cell
count
current
recommend
routin
screen
cmv
patient
mm
daratumumab
treatment
howev
cmv
reactiv
alway
consid
patient
mm
treat
daratumumab
novel
agent
immunosuppress
effect
develop
fever
complaint
otherwis
explain
zweegman
serv
advisori
board
celgen
janssen
pharmaceut
takeda
amgen
sanofi
receiv
research
fund
celgen
janssen
pharmaceut
takeda
nwcj
van
de
donk
serv
advisori
board
janssen
pharmaceut
celgen
amgen
novarti
bayer
servier
receiv
research
support
janssen
pharmaceut
celgen
amgen
bm
author
state
conflict
interest
